

**Table 15k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions**

**Updated:** Apr.11, 2022  
**Reviewed:** Apr.11, 2022

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
<b>Rash</b>	<ul style="list-style-type: none"> <li>Any ARV drug can cause rash.</li> </ul>	<p><b>Onset</b></p> <ul style="list-style-type: none"> <li>First few days to weeks after starting new ARV drug(s)</li> </ul> <p><b>Presentation</b></p> <ul style="list-style-type: none"> <li>Most rashes mild to moderate diffuse maculopapular eruptions</li> </ul> <p><b>Note:</b> A rash can be the initial manifestation of systemic hypersensitivity (see the SJS/TEN/EM major and HSR sections below).</p>	<p><b>Common (&gt;10%)</b></p> <ul style="list-style-type: none"> <li>EFV</li> <li>ETR</li> <li>FTC</li> <li>NVP</li> </ul> <p><b>Less Common (5% to 10%)</b></p> <ul style="list-style-type: none"> <li>ABC</li> <li>ATV</li> <li>DRV</li> <li>TDF</li> </ul> <p><b>Unusual (2% to 4%)</b></p> <ul style="list-style-type: none"> <li>BIC</li> <li>LPV/r</li> <li>MVC</li> <li>RAL</li> <li>RPV</li> </ul>	<ul style="list-style-type: none"> <li>Sulfonamide allergy is a risk factor for rash in patients who are taking PIs that contain a sulfonamide moiety (i.e., DRV).</li> <li>Polymorphisms in CYP2B6 and multiple HLA loci are associated with an increased risk of rash in patients who are taking NVP.</li> </ul>	<p><b>When Starting NVP or Restarting NVP After Interruptions of &gt;14 Days</b></p> <ul style="list-style-type: none"> <li>Utilize once-daily lead-in dosing.<sup>a</sup> This may not be necessary in children ages &lt;2 years.<sup>b</sup></li> <li>Avoid the use of systemic corticosteroids during NVP dose escalation.</li> <li>Assess the patient for rash severity, mucosal involvement, and other signs of systemic reaction.</li> </ul>	<p><b>Mild-to-Moderate Maculopapular Rash Without Systemic or Mucosal Involvement</b></p> <ul style="list-style-type: none"> <li>Most rashes will resolve without intervention; ARV drugs can be continued while monitoring.<sup>a</sup></li> <li>Antihistamines may provide some relief.</li> </ul> <p><b>Severe Rash and/or Rash Accompanied by Systemic Symptoms</b></p> <ul style="list-style-type: none"> <li>Manage as SJS/TEN/EM major, DRESS, or HSR as applicable (see below).</li> </ul> <p><b>Rash in Patients Receiving NVP</b></p> <ul style="list-style-type: none"> <li>Given the elevated risk of HSR, measure hepatic transaminases.</li> <li>If hepatic transaminases are elevated, NVP <b>should be discontinued and not restarted</b> (see the HSR section below).</li> </ul>
<b>SJS/TEN/EM Major</b>	<ul style="list-style-type: none"> <li>Many ARV drugs, especially NNRTIs (see the Estimated Frequency column)</li> </ul>	<p><b>Onset</b></p> <ul style="list-style-type: none"> <li>First few days to weeks after starting new ARV drug(s)</li> </ul> <p><b>Presentation</b></p> <ul style="list-style-type: none"> <li>Initial rash may be mild, but it often becomes painful,</li> </ul>	<p><b>Infrequent</b></p> <ul style="list-style-type: none"> <li>NVP (0.3%)</li> <li>EFV (0.1%)</li> <li>ETR (&lt;0.1%)</li> </ul> <p><b>Case Reports</b></p> <ul style="list-style-type: none"> <li>ABC</li> </ul>	<p><b>Adults</b></p> <ul style="list-style-type: none"> <li>Female sex</li> <li>Patients who are Black, Asian, or Hispanic at higher risk</li> </ul>	<p><b>When Starting NVP or Restarting NVP After Interruptions of &gt;14 Days</b></p> <ul style="list-style-type: none"> <li>Utilize once-daily lead-in dosing.<sup>a</sup> This may not be necessary in children aged &lt;2 years.<sup>b</sup></li> </ul>	<ul style="list-style-type: none"> <li>Discontinue all ARV drugs and other possible causative agents (e.g., TMP-SMX).</li> <li>Provide intensive supportive care, including IV hydration, aggressive wound care, eye care, labial adhesion preventive care, pain management, and antipyretics.</li> </ul>

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
		<p>evolving to blister/bulla formation with necrosis in severe cases. Usually involves mucous membrane ulceration and/or conjunctivitis.</p> <ul style="list-style-type: none"> <li>• Systemic symptoms may also include fever, tachycardia, malaise, myalgia, and arthralgia.</li> </ul>	<ul style="list-style-type: none"> <li>• ATV</li> <li>• DRV</li> <li>• LPV/r</li> <li>• RAL</li> <li>• ZDV</li> </ul>		<ul style="list-style-type: none"> <li>• Counsel families to report symptoms as soon as they appear.</li> </ul>	<p>Parenteral nutrition and antibiotics may also be necessary.</p> <ul style="list-style-type: none"> <li>• Corticosteroids and/or IVIG are sometimes used, but the use of these interventions is controversial.</li> <li>• <b>Do not reintroduce</b> the offending medication.</li> <li>• In cases where a patient experiences SJS/TEN/EM major while taking an NNRTI, many experts would avoid using other NNRTIs when restarting ART.</li> </ul>
<b>DRESS</b>	<ul style="list-style-type: none"> <li>• DRV, DTG, EFV, ETR, NVP, RAL, RPV</li> </ul>	<p><b>Onset</b></p> <ul style="list-style-type: none"> <li>• 1–8 weeks after starting new ARV drug(s)</li> </ul> <p><b>Presentation</b></p> <ul style="list-style-type: none"> <li>• Fever</li> <li>• Lymphadenopathy</li> <li>• Facial swelling</li> <li>• Morbilliform to polymorphous rash</li> <li>• Peripheral eosinophilia</li> <li>• Atypical circulating lymphocytes</li> <li>• Internal organ involvement (particularly the liver and/or kidneys)</li> </ul>	<ul style="list-style-type: none"> <li>• Rare</li> </ul>	<ul style="list-style-type: none"> <li>• Unknown</li> <li>• Potential association with HLA-B*53:01 and RAL-induced DRESS</li> </ul>	<ul style="list-style-type: none"> <li>• Obtain a CBC and AST, ALT, and creatinine levels from patients who present with suggestive symptoms.</li> </ul>	<ul style="list-style-type: none"> <li>• Discontinue all ARV drugs and other possible causative agents (e.g., TMP-SMX).</li> <li>• The role of systemic steroids or IVIG in treatment is unclear; consultation with a specialist is recommended.</li> <li>• Provide supportive care for end-organ disease.</li> <li>• <b>Do not reintroduce</b> the offending medication.</li> </ul>
<b>HSR</b>	ABC	<p><b>Onset</b></p> <p><i>With First Use</i></p>	<ul style="list-style-type: none"> <li>• &lt;1% to 9% (varies by ethnicity)</li> </ul>	<ul style="list-style-type: none"> <li>• HLA-B*5701 (HSR is very uncommon in people who are HLA-B*5701 negative).</li> </ul>	<ul style="list-style-type: none"> <li>• Screen for HLA-B*5701. <b>ABC should not be prescribed if HLA-B*5701 is present.</b> The</li> </ul>	<ul style="list-style-type: none"> <li>• Discontinue all ARV drugs and investigate other causes of the symptoms (e.g., a concurrent viral illness).</li> </ul>

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
and excluding SJS/TEN		<ul style="list-style-type: none"> <li>• Within first 6 weeks of initiating ABC</li> </ul> <p><i>With Reintroduction</i></p> <ul style="list-style-type: none"> <li>• Within hours of initiating ABC</li> </ul> <p><b>Presentation</b></p> <ul style="list-style-type: none"> <li>• Symptoms include high fever, diffuse skin rash, malaise, nausea, headache, myalgia, arthralgia, diarrhea, vomiting, abdominal pain, pharyngitis, and respiratory symptoms (e.g., dyspnea).</li> <li>• With continuation of ABC, symptoms may progress to hypotension and vascular collapse. With rechallenge, symptoms can mimic anaphylaxis.</li> </ul>		<ul style="list-style-type: none"> <li>• The risk of HSR is higher in patients who are white than in patients who are Black or East Asian.</li> </ul>	<p>medical record should clearly indicate that ABC is <b>contraindicated</b> in these patients.</p> <ul style="list-style-type: none"> <li>• When starting ABC, counsel patients and families about the signs and symptoms of HSR to ensure prompt reporting of reactions.</li> </ul>	<ul style="list-style-type: none"> <li>• Provide symptomatic treatment.</li> <li>• Most symptoms resolve within 48 hours after discontinuing ABC.</li> </ul> <p><b>Do not rechallenge</b> with ABC even if the patient is HLA-B*5701 negative.</p>
	NVP	<p><b>Onset</b></p> <ul style="list-style-type: none"> <li>• Occurs most frequently in the first few weeks of therapy but can occur through 18 weeks.</li> </ul> <p><b>Presentation</b></p> <ul style="list-style-type: none"> <li>• Flu-like symptoms (including nausea, vomiting, myalgia, fatigue, fever, abdominal pain, and jaundice) with or</li> </ul>	<ul style="list-style-type: none"> <li>• Occurs in 4% of patients on average, with a range of 2.5% to 11%</li> </ul>	<p><b>Adults</b></p> <ul style="list-style-type: none"> <li>• ARV-naive with a higher CD4 count (&gt;250 cells/mm<sup>3</sup> in women; &gt;400 cells/mm<sup>3</sup> in men)</li> <li>• Female sex (risk is threefold higher in females than in males).</li> </ul> <p><b>Children</b></p> <ul style="list-style-type: none"> <li>• NVP hepatotoxicity and HSR are less common in prepubertal children</li> </ul>	<p><b>When Starting NVP or Restarting NVP After Interruptions of &gt;14 Days</b></p> <ul style="list-style-type: none"> <li>• A 2-week lead-in period with once-daily dosing, followed by dose escalation to twice daily as recommended, may reduce the risk of reaction.<sup>a</sup> This may not be necessary in children aged &lt;2 years.<sup>b</sup></li> <li>• Counsel families about signs and symptoms of</li> </ul>	<ul style="list-style-type: none"> <li>• Discontinue all ARV drugs.</li> <li>• Consider other causes of hepatitis and discontinue all hepatotoxic medications.</li> <li>• Provide supportive care as indicated, and monitor the patient closely.</li> <li>• <b>Do not reintroduce NVP.</b> It is unclear whether it is safe to use other NNRTIs after a patient experiences symptomatic hepatitis due to NVP, and many experts</li> </ul>

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
		without skin rash that may progress to hepatic failure with encephalopathy		<p>than in adults, and both are uncommon in infants.</p> <ul style="list-style-type: none"> <li>High CD4 percentage is associated with an increased risk of NVP toxicity. In the PREDICT Study, the risk of NVP toxicity (rash, hepatotoxicity, and hypersensitivity) was 2.65 times greater in children who had CD4 percentages <math>\geq 15\%</math> than in children who had CD4 percentages <math>&lt; 15\%</math>.</li> </ul>	<p>HSR to ensure prompt reporting of reactions.</p> <ul style="list-style-type: none"> <li>Obtain AST and ALT levels in patients with rash. Obtain AST and ALT levels at baseline, before dose escalation, 2 weeks after dose escalation, and thereafter at 3-month intervals.</li> <li>Avoid NVP use in women with CD4 counts <math>&gt; 250</math> cells/mm<sup>3</sup> and in men with CD4 counts <math>&gt; 400</math> cells/mm<sup>3</sup>, unless benefits outweigh risks.</li> <li>Do not use NVP as PEP outside of the neonatal period.</li> </ul>	would avoid the NNRTI drug class when restarting treatment.
	ETR	<p><b>Onset</b></p> <ul style="list-style-type: none"> <li>Any time during therapy</li> </ul> <p><b>Presentation</b></p> <ul style="list-style-type: none"> <li>Symptoms may include rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure.</li> </ul>	<ul style="list-style-type: none"> <li>Rare</li> </ul>	<ul style="list-style-type: none"> <li>Unknown</li> </ul>	<ul style="list-style-type: none"> <li>Evaluate for hypersensitivity if the patient is symptomatic.</li> </ul>	<ul style="list-style-type: none"> <li>Discontinue all ARV drugs.</li> <li>Rechallenge with ETR is <b>not recommended</b>.</li> </ul>
	MVC	<ul style="list-style-type: none"> <li>Rash preceding hepatotoxicity</li> </ul>	<ul style="list-style-type: none"> <li>Rare</li> </ul>	<ul style="list-style-type: none"> <li>Unknown</li> </ul>	<ul style="list-style-type: none"> <li>Obtain AST and ALT levels from patients with rash or other symptoms of hypersensitivity.</li> </ul>	<ul style="list-style-type: none"> <li>Discontinue all ARV drugs.</li> <li>Rechallenge with MVC is <b>not recommended</b>.</li> </ul>

Adverse Effects	Associated ARVs	Onset/Clinical Manifestations	Estimated Frequency	Risk Factors	Prevention/Monitoring	Management
	<ul style="list-style-type: none"> <li>DTG</li> </ul>	<ul style="list-style-type: none"> <li>Rash with hepatic dysfunction</li> </ul>	<ul style="list-style-type: none"> <li>Rare</li> </ul>	<ul style="list-style-type: none"> <li>Unknown</li> </ul>	<ul style="list-style-type: none"> <li>Obtain AST and ALT levels from patients with rash or other symptoms of hypersensitivity.</li> </ul>	<ul style="list-style-type: none"> <li>Discontinue all ARV drugs.</li> <li>Rechallenge with DTG is <b>contraindicated</b>.</li> </ul>

<sup>a</sup> The prescribing information for NVP states that patients who experience rash during the 14-day lead-in period should not have the NVP dose increased until the rash has resolved. However, prolonging the lead-in phase beyond 14 days may increase the risk of NVP resistance because of subtherapeutic drug levels. Children who have persistent mild or moderate rash after the lead-in period should receive individualized care. Consult an expert in HIV care when managing these patients. **NVP should be stopped and not restarted** if the rash is severe or progressing. See the [Nevirapine](#) section of the Drug Appendix.

<sup>b</sup> Lead-in dosing **is not recommended** when using NVP for either presumptive or definitive HIV therapy in newborns with perinatal HIV exposure or perinatal HIV infection. See the [Nevirapine](#) section of the Drug Appendix and [Table 12 in Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#).

**Key:** ABC = abacavir; ALT = alanine transaminase; ART = antiretroviral therapy; ARV = antiretroviral; AST = aspartate aminotransferase; ATV = atazanavir; BIC = bictegravir; CBC = complete blood count; CD4 = CD4 T lymphocyte; CYP2B6 = Cytochrome P450 Family 2 Subfamily B Member 6; DRESS = drug reaction (or rash) with eosinophilia and systemic symptoms; DRV = darunavir; DTG = dolutegravir; EFV = efavirenz; EM = erythema multiforme; ETR = etravirine; FTC = emtricitabine; HLA = human leukocyte antigen; HLA-B\*5701 = human leucocyte antigen gene variant; HSR = hypersensitivity reaction; IV = intravenous; IVIG = intravenous immune globulin; LPV/r = lopinavir/ritonavir; MVC = maraviroc; NNRTI = non-nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PEP = post-exposure prophylaxis; PI = protease inhibitor; PREDICT Study = Personalised Responses to Dietary Composition Trial Study; RAL = raltegravir; RPV = rilpivirine; SJS = Stevens-Johnson syndrome; TDF = tenofovir disoproxil fumarate; TEN = toxic epidermal necrolysis; TMP-SMX = trimethoprim-sulfamethoxazole; ZDV = zidovudine

## References

1. Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Castera E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. *J Antimicrob Chemother.* 2008;62(5):879-888. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18653488>.
2. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. *Clin Infect Dis.* 2000;30(1):227-228. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10619772>.
3. du Toit JD, Kotze K, van der Westhuizen HM, Gaunt TL. Nevirapine-induced Stevens-Johnson syndrome in children living with HIV in South Africa. *South Afr J HIV Med.* 2021;22(1):1182. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33824730>.
4. Dziuban EJ, Hughey AB, Stewart DA, et al. Stevens-Johnson syndrome and HIV in children in Swaziland. *Pediatr Infect Dis J.* 2013;32(12):1354-1358. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23743542>.
5. Fillekes Q, Mulenga V, Kabamba D, et al. Is nevirapine dose escalation appropriate in young, African, HIV-infected children? *AIDS.* 2013;27(13):2111-2115. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23595153>.
6. Hasan M, Yuniastuti E, Abdullah M. Incidence and predictors of nevirapine and efavirenz-associated rash among Indonesian HIV patients. *Asian Pac J Allergy Immunol.* 2020;12932/AP-080719-0596. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32061245>.
7. Hayes E, Derrick C, Smalls D, Smith H, Kremer N, Weissman S. Short-term adverse events with BIC/FTC/TAF: postmarketing study. *Open Forum Infect Dis.* 2020;7(9):ofaa285. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32908943>.
8. Kim GY, Anderson KR, Davis DMR, Hand JL, Tollefson MM. Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: a systematic review of the literature. *J Am Acad Dermatol.* 2020;83(5):1323-1330. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32247873>.
9. Lefebvre M, Walencik A, Allavena C, et al. Rate of DRESS syndrome with raltegravir and role of the HLA-B\*53:01 allele. *J Acquir Immune Defic Syndr.* 2020;85(4):e77-e80. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33136758>.
10. Mallal S, Phillips E, Carosi G, et al. HLA-B\*57:01 screening for hypersensitivity to abacavir. *N Engl J Med.* 2008;358(6):568-579. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18256392>.
11. Martin C, Payen MC, De Wit S. Dolutegravir as a trigger for DRESS syndrome? *Int J STD AIDS.* 2018;29(10):1036-1038. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29621952>.
12. Mounzer K, Hsu R, Fusco JS, et al. HLA-B\*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA((R)) observational database: a cohort study. *AIDS Res Ther.* 2019;16(1):1. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30651100>.
13. Nachman S, Alvero C, Teppler H, et al. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial. *Lancet HIV.* 2018;5(12):e715-e722. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30527329>.

14. Nishijima T, Gatanaga H, Teruya K, et al. Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting. *J Infect Chemother*. 2014;20(4):285-287. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24507978>.
15. Perry ME, Almaani N, Desai N, Larbalestier N, Fox J, Chilton D. Raltegravir-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome—implications for clinical practice and patient safety. *Int J STD AIDS*. 2013;24(8):639-642. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23970584>.
16. Peter J, Choshi P, Lehloenya RJ. Drug hypersensitivity in HIV infection. *Curr Opin Allergy Clin Immunol*. 2019;19(4):272-282. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31145192>.
17. Prasertvit P, Chareonyingwattana A, Wattanakrai P. Nevirapine patch testing in Thai human immunodeficiency virus–infected patients with nevirapine drug hypersensitivity. *Contact Dermatitis*. 2017;77(6):379-384. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28782122>.
18. Puthanakit T, Bunupuradah T, Kosalaraksa P, et al. Prevalence of human leukocyte antigen-B\*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use. *Pediatr Infect Dis J*. 2013;32(3):252-253. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22986704>.
19. Ripamonti D, Benatti SV, Di Filippo E, Ravasio V, Rizzi M. Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: case report and review of the literature. *AIDS*. 2014;28(7):1077-1079. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24685746>.
20. Rutstein RM, Samson P, Fenton T, et al. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group protocol 1020A. *Pediatr Infect Dis J*. 2015;34:162-167. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25232777>.
21. Shah R, Nabiswa H, Okinda N, Revathi G, Hawken M, Nelson M. Prevalence of HLA-B\*5701 in a Kenyan population with HIV infection. *J Infect*. 2018;76(2):212-214. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28919349>.
22. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. *AIDS*. 2013;27(9):1403-1412. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23343913>.
23. Thomas M, Hopkins C, Duffy E, et al. Association of the HLA-B\*53:01 allele with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome during treatment of HIV infection with raltegravir. *Clin Infect Dis*. 2017;64(9):1198-1203. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28369189>.
24. Thomas SJ, Kilgore JT, Becken BA, Cunningham CK, Thompson AB. Raltegravir-associated drug-reaction with eosinophilia and systemic symptoms syndrome in a pediatric patient without characteristic human leukocyte antigen B\*57:01 or B\*53:01 alleles. *J Pediatric Infect Dis Soc*. 2021;10(3):363-366. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32766769>.
25. Tudor-Williams G, Cahn P, Chokephaibulkit K, et al. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study. *HIV Med*. 2014;15(9):513-524. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24589294>.

26. Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1\*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. *AIDS*. 2008;22(4):540-541. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18301070>.
27. Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. *AIDS*. 2011;25(10):1271-1280. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21505298>.